Navigation Links
Cardiome to Present at ThinkEquity Conference
Date:9/17/2007

in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results ex
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... (PORTLAND, Ore.) October 27, 2008 Elderly people who have ... abstention from tobacco, moderate to higher income and no ... their old age, according to a study in ... Medical Sciences . , The first study of its ...
... took them were less likely to get venous thromboembolism ... of drugs widely used to lower cholesterol may have ... breast, lung, colon and other solid-organ cancers. , Research ... Philadelphia found that cancer patients taking statins had a ...
... Reduce the Risk of a Subsequent Stroke, AUSTIN, ... launch of The TIA (Transient Ischemic Attack) Center for,Stroke ... of its kind in,Central Texas -- in an effort ... TIA., A TIA is a "warning stroke" or ...
... Incomparable Nutrient Value for Less Than 25 Cents A ... ... just released by,consulting firm Booz & Company confirmed that U.S. consumers have ... one,third of consumers have made measurable cutbacks in frequent purchases,such as dining ...
... Data presented at the joint annual meeting of ICAAC and ... effective as Prevnar for,the seven shared serotypes, and provide expanded ... complete U.S. filing for pediatric use in the first,quarter of ... or possibly earlier, WASHINGTON, Oct. 27 Data from ...
... ... Finds, RICHMOND, Va., Oct. 27 Eighty-four ... funding will be an important factor in determining how they cast,their vote in ... to 64 sponsored by Genworth Financial, Inc.,(NYSE: GNW )., According to ...
Cached Medicine News:Health News:Study reveals factors of exceptional health in old age 2Health News:Statins Lower Risk of Clots in Cancer Patients 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 3Health News:No Need to Forego Nutrition in Tight Economic Times 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 3Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 4Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 5Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 6Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 7Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 2Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 3
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 2, 2011 Doctors should consider using catheterization as ... in diagnosing children with heart defects, according to a ... (Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) A catheter is ... and used in procedures such as angiography, in which ...
... Lpath, Inc. (OTCBB: LPTN), the category leader ... President and CEO, will present at RetailInvestorConferences.com.DATE: ... EDTLINK: , www.retailinvestorconferences.com >Click the red "register/ ... interactive online event where investors are invited to ...
Cached Medicine Technology:Catheterization Recommended for Treating Pediatric Heart Conditions 2Catheterization Recommended for Treating Pediatric Heart Conditions 3Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 2Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 3
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Round knurled handle. Overall length 130 mm....
Medicine Products: